Cardan Capital Partners LLC Has $3,764,000 Position in Gilead Sciences Inc. (GILD)
Cardan Capital Partners LLC cut its position in Gilead Sciences Inc. (NASDAQ:GILD) by 1.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 45,122 shares of the biopharmaceutical company’s stock after selling 521 shares during the period. Cardan Capital Partners LLC’s holdings in Gilead Sciences were worth $3,764,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of GILD. Temasek Holdings Private Ltd increased its position in shares of Gilead Sciences by 8.1% in the first quarter. Temasek Holdings Private Ltd now owns 13,830,516 shares of the biopharmaceutical company’s stock worth $1,270,471,000 after buying an additional 1,035,592 shares during the period. Geode Capital Management LLC increased its position in shares of Gilead Sciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 12,410,846 shares of the biopharmaceutical company’s stock worth $1,137,969,000 after buying an additional 161,505 shares during the period. Bank of Montreal Can bought a new position in shares of Gilead Sciences during the second quarter worth $427,750,000. Canada Pension Plan Investment Board increased its position in shares of Gilead Sciences by 15.6% in the first quarter. Canada Pension Plan Investment Board now owns 4,955,996 shares of the biopharmaceutical company’s stock worth $455,258,000 after buying an additional 669,800 shares during the period. Finally, Prudential Financial Inc. increased its position in shares of Gilead Sciences by 12.0% in the first quarter. Prudential Financial Inc. now owns 3,816,408 shares of the biopharmaceutical company’s stock worth $350,575,000 after buying an additional 410,120 shares during the period. 77.93% of the stock is currently owned by institutional investors.
Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded up 0.33% during trading on Monday, hitting $75.49. The stock had a trading volume of 7,146,889 shares. The company has a market cap of $99.62 billion, a P/E ratio of 6.63 and a beta of 1.10. The stock has a 50-day moving average price of $78.95 and a 200 day moving average price of $85.05. Gilead Sciences Inc. has a 12 month low of $74.92 and a 12 month high of $111.11.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.02 by $0.06. The firm had revenue of $7.78 billion for the quarter, compared to the consensus estimate of $7.80 billion. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The company’s revenue for the quarter was down 5.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.15 EPS. Equities analysts expect that Gilead Sciences Inc. will post $11.76 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 29th. Shareholders of record on Friday, September 16th were given a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 2.49%. The ex-dividend date of this dividend was Wednesday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 16.56%.
A number of equities analysts recently weighed in on GILD shares. Credit Suisse Group AG cut their price target on shares of Gilead Sciences from $115.00 to $95.00 and set an “outperform” rating on the stock in a report on Wednesday, September 14th. Morgan Stanley reissued a “hold” rating and issued a $103.00 price target on shares of Gilead Sciences in a report on Wednesday, June 15th. Jefferies Group reissued a “hold” rating on shares of Gilead Sciences in a report on Thursday, August 25th. Piper Jaffray Cos. reissued an “overweight” rating on shares of Gilead Sciences in a report on Tuesday, August 16th. Finally, S&P Equity Research reissued a “strong-buy” rating on shares of Gilead Sciences in a report on Wednesday, July 27th. Ten investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $104.71.
In other Gilead Sciences news, insider John C. Martin sold 100,000 shares of the company’s stock in a transaction on Thursday, September 1st. The stock was sold at an average price of $77.48, for a total value of $7,748,000.00. Following the transaction, the insider now owns 3,287,810 shares of the company’s stock, valued at approximately $254,739,518.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kevin E. Lofton sold 3,500 shares of the company’s stock in a transaction on Wednesday, August 24th. The shares were sold at an average price of $81.97, for a total value of $286,895.00. The disclosure for this sale can be found here. 1.40% of the stock is owned by company insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.